Steatohepatitis/Metabolic Liver Disease News

Among patients with severe hypertriglyceridemia who underwent MRI proton density fat fraction, clinically meaningful hepatic steatosis appeared to be common, according to a presenter at the National Lipid Association Scientific Sessions.

Healio Gastroenterology and Hepatology presents the following report on recent stories from the Digital NAFLD Summit 2021.

Nonalcoholic fatty liver disease correlated with an increased long-term risk for cardiovascular events and may be an independent risk factor for CVD morbidity and mortality, according to research.

Pioglitazone was safe and effective in improving liver histology among patients with nonalcoholic steatohepatitis, according to a presenter at the Digital NAFLD Summit 2021.

Two doses of icosabutate were well tolerated and safe in patients with nonalcoholic steatohepatitis.

Researchers developed a consensus statement that demonstrated the increased need for support in addressing nonalcoholic fatty liver disease as a global public health problem, according to a presentation at the Digital NAFLD Summit 2021.

The temporal change rate of proton density fat fraction and liver stiffness measurement are promising predictors for those at high risk for rapid clinical progression and may improve patient management in those with nonalcoholic fatty liver disease.

Researchers identified more patients with fatty liver disease using novel metabolic dysfunction-associated fatty liver disease criteria compared with nonalcoholic fatty liver disease criteria.

Severe nonalcoholic fatty liver disease may be correlated with Autophagy Related Gene 7 loss-of-function variants, which may impair hepatocellular ballooning and inflammation.

Regarding cardiovascular mortality, results published in the Scandinavian Journal of Gastroenterology demonstrated a negative interaction between fatty liver disease and hypertension in nondiabetic men.